KICKING GOALS ON THE GOLD COAST

Icon Cancer Centre Gold Coast University Hospital (GCUH) and Icon Cancer Centre

Gold Coast Private have had a milestone year of delivering radiation oncology clinical trials.

Gold Coast based Principal Investigators, Dr Eric Khoo and Dr Andrew Oar alongside Senior Clinical Research Coordinator, Hayley Brennan have delivered impressive growth with several highest State recruitments and the activation of Investigator Initiated Trials and projects.

The 2022 calendar year continued the recruitment to the DASL HiCAP trial, with the team screening over 40 patients and recruiting 12. DASL HiCAP is a randomised Phase III double-blinded trial assessing the addition of a new oral hormone drug, darolutamide to the standard of care treatment for very high-risk prostate cancer patients.

Icon Gold Coast was the highest recruiting site in Queensland, third highest in Australia and sixth globally. Gold Coast was also the state’s highest recruiter and second nationally for the MASTERPLAN trial - a randomised phase II study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer with High Risk and Locally Advanced Disease.

In 2023 and beyond, the team is expected to activate the CONSOLE trial – an Investigator Initiated Phase III trial looking at conventional or stereotactic radiation therapy for the palliation of non-spine bone metastases. The sites are targeting to recruit 10 – 20 patients, setting a goal for high recruitment within Queensland participating sites.

The team is focused on activating new trials that will meet KPIs for Icon and Queensland Health, with a particular interest in breast and gastrointestinal cancer trials. In the latter half of 2023, Icon Cancer Centre GCUH will have an additional Varian linac equipped with HyperArc which will increase contribution to the HyperArc registry and continue to provide opportunities for further in-house research, including cross site collaboration and radiation therapist, nursing and medical physics led trials.

Highest Queensland recruiter for

Australia’s 2nd highest recruitment to the MASTERPLAN trial

2nd Australia site activated for the Varian HyperArc registry

1st 2023

CONSOLE trial activation set for